









Markets
/
Stocks
/
nasdaq-fold
/

Amicus Therapeutics Inc

FOLD

8.330USD

-0.150-1.77%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.57BMarket Cap

LossP/E TTM



Amicus Therapeutics Inc

8.330

-0.150-1.77%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

20 / 506

Overall Ranking

95 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

15.727

Target Price

+85.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 60.46% year-on-year.

Undervalued

The company’s latest PE is -67.91, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 324.80M shares, decreasing 1.10% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 29.35M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.23, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 154.69M, representing a year-over-year increase of 22.12%, while its net profit experienced a year-over-year increase of 55.57%.

Score

Industry at a Glance

Previous score

8.23

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.42

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.51

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -69.13, which is -13.44% below the recent high of -59.84 and 5.40% above the recent low of -65.40.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Amicus Therapeutics Inc is 15.00, with a high of 22.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

15.727

Target Price

+85.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Amicus Therapeutics Inc

FOLD

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.97, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 8.90 and the support level at 7.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.97

Change

-0.29

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Neutral

RSI(14)

66.826

Neutral

STOCH(KDJ)(9,3,3)

76.245

Buy

ATR(14)

0.310

Low Volatility

CCI(14)

170.334

Buy

Williams %R

20.765

Buy

TRIX(12,20)

0.569

Sell

StochRSI(14)

63.979

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

8.104

Buy

MA10

8.034

Buy

MA20

7.879

Buy

MA50

7.103

Buy

MA100

6.631

Buy

MA200

7.794

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 105.37%, representing a quarter-over-quarter increase of 1.60%. The largest institutional shareholder is The Vanguard, holding a total of 29.35M shares, representing 9.52% of shares outstanding, with 2.51% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

29.00M

-0.71%

Wellington Management Company, LLP

29.20M

+2.60%

BlackRock Institutional Trust Company, N.A.

22.92M

-0.95%

Avoro Capital Advisors LLC

20.50M

-11.54%

William Blair Investment Management, LLC

14.78M

-5.25%

Vestal Point Capital, LP

4.28M

+27.61%

State Street Global Advisors (US)

9.52M

-8.13%

Macquarie Investment Management

6.82M

+2.82%

Millennium Management LLC

3.36M

+635.07%

Perceptive Advisors LLC

21.46M

-11.47%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.22, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.55. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.